Search
Phenserine
go.drugbank.com/drugs/DB04892InvestigationalUnlike currently marketed AChE inhibitors, it has a dual mechanism of action that also includes anti-amyloid activity, which may confer disease-modifying effects in patients with AD. … Phenserine is under development by Axonyx, a US biopharmaceutical company that focuses on treatments for dementia.
Verpasep caltespen
go.drugbank.com/drugs/DB04959InvestigationalE7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes. … It is being developed by StressGen Biotechnologies Corp.
Flumequine
go.drugbank.com/drugs/DB08972ApprovedWithdrawnFlumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.
Categories: Topoisomerase II InhibitorsNV-07a
go.drugbank.com/drugs/DB05845ExperimentalNV-07a is topical skin repair compound protecting skin from sun-induced immunosuppression and UV-induced damage.
Alferminogene tadenovec
go.drugbank.com/drugs/DB05306InvestigationalAlferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease … Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard
NCX 701
go.drugbank.com/drugs/DB05409ExperimentalNitroparacetamol (NCX-701) is a newly synthesized nitric oxide-releasing derivative of paracetamol.
Tesevatinib
go.drugbank.com/drugs/DB11973InvestigationalIn addition, tesevatinib inhibits EphB4, an RTK that is highly expressed in many human tumors and plays a role in promoting angiogenesis. … Tesevatinib is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation).
Edonerpic
go.drugbank.com/drugs/DB05938InvestigationalEdonerpic is a neurotrophic agent intended for the treatment of Alzheimer's disease which is under phase I clinical trial.
GPI-1485
go.drugbank.com/drugs/DB05814InvestigationalGPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ligands. … GPI 1485 is being studied in phase 2 clinical trials for the treatment of Parkinson's disease and post-prostatectomy erectile dysfunction and in pre-clinical development for HIV related dementia and neuropathy
Oportuzumab monatox
go.drugbank.com/drugs/DB05319InvestigationalVB4-845 is studied in the treatment of certain types of head and neck cancer. VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells. … VB4-845 is a fusion protein containing humanized scFv specific for the epithelial cell adhesion molecule, Ep-CAM, a tumor cell-associated target highly expressed on carcinoma cells of epithelial origin